<DOC>
	<DOCNO>NCT00498186</DOCNO>
	<brief_summary>This multi-center , open-label extension trial conduct European site participate trial SP 709 ( NCT00243217 ) . The trial design collect long-term safety tolerability , efficacy correlate , quality life data subject idiopathic Restless Leg Syndrome ( RLS ) . The duration treatment approximately 5 year . Subject up-titrated optimal dose ( administration 1 patch per day , 5 different dos patch size ) .</brief_summary>
	<brief_title>Long-term Open-label Trial Idiopathic Restless Legs Syndrome ( RLS )</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Psychomotor Agitation</mesh_term>
	<mesh_term>Restless Legs Syndrome</mesh_term>
	<mesh_term>N 0437</mesh_term>
	<criteria>Subject complete precede trial SP709 ( NCT00243217 ) Subject suffer serious adverse event trial SP709 ( NCT00243217 ) ongoing end trial assess related study medication investigator and/or Sponsor Sleep disturbances Further clinically relevant concomitant diseases polyneuropathy , akathisia , claudication , varicosis , muscle fasciculation , painful leg move toe , radiculopathy Other central nervous disease One psychotic episode since start study SP709 Any medical psychiatric condition , opinion investigator jeopardize would compromise subject 's ability participate trial Clinically relevant cardiac dysfunction arrhythmia The subject entry study SP710 , QTc interval ≥ 500 msec and/or QTc interval increase ≥ 60 msec compare average baseline ( Visit 2 ) QTc interval study SP709 Subject clinically relevant renal dysfunction ( serum creatine ≥ 2.0 mg/dl ) Subject clinically relevant hepatic dysfunction ( total bilirubin &gt; 2.0 mg/dl ALT and/or AST great two time upper limit reference range Subject newly diagnose relapse neoplastic disease since start study SP709 Subject know hypersensitivity component trial medication comparative drug state protocol Subject need drug prohibit course trial : neuroleptic , bupidine , hypnotic , antidepressant , anxiolytic drug , anticonvulsive therapy , psychostimulatory drug , LDopa dopamine agonist therapy , opioids , benzodiazepine , MAO inhibitor , sedative antihistamine , amphetamine Subject abuse alcohol drug since start SP709 Subject pregnant nursing woman childbearing potential surgically sterile , two year postmenopausal , practice two combine method contraception , unless sexually abstinent Subject pursues shift work subject continuous nondiseaserelated life condition allow regular sleep night Subject clinically relevant vasculopathies ( eg , varix arteriosclerosis ) Subject significant skin hypersensitivity adhesive transdermals recent unresolved contact dermatitis Subject symptomatic orthostatic hypotension , systolic blood pressure ( SBP ) less tham 105mmHg and/or drop SBP &gt; 20mmHg drop &gt; 10mmHg diastolic BP ( DBP ) stand baseline visit ( Visit 1 )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Rotigotine</keyword>
	<keyword>Neupro®</keyword>
</DOC>